488 related articles for article (PubMed ID: 33077515)
1. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.
Cortellini A; Ricciuti B; Tiseo M; Bria E; Banna GL; Aerts JG; Barbieri F; Giusti R; Cortinovis DL; Migliorino MR; Catino A; Passiglia F; Torniai M; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Rastelli F; Chiari R; Rocco D; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Grossi F; Filetti M; Pizzutilo P; Russano M; Citarella F; Cantini L; Targato G; Nigro O; Ferrara MG; Buti S; Scodes S; Landi L; Guaitoli G; Della Gravara L; Tabbò F; Ricciardi S; De Toma A; Friedlaender A; Petrelli F; Addeo A; Porzio G; Ficorella C
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077515
[TBL] [Abstract][Full Text] [Related]
2. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H; Kishikawa T; Minemura H; Yamada Y; Ibe T; Yamaguchi O; Mouri A; Hamamoto Y; Kanazawa K; Kasai T; Kaira K; Kaburagi T; Minato K; Kobayashi K; Kagamu H
Cancer Med; 2021 Oct; 10(20):6971-6984. PubMed ID: 34414673
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
6. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50.
Cortellini A; Tiseo M; Banna GL; Cappuzzo F; Aerts JGJV; Barbieri F; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Santini D; Berardi R; Morabito A; Genova C; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Santoni M; Tudini M; Rijavec E; Filetti M; Catino A; Pizzutilo P; Sala L; Citarella F; Marco R; Torniai M; Cantini L; Targato G; Sforza V; Nigro O; Ferrara MG; D'Argento E; Buti S; Bordi P; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Della Gravara L; Dal Bello MG; Belderbos RA; Bironzo P; Carnio S; Ricciardi S; Grieco A; De Toma A; Proto C; Friedlaender A; Cantale O; Ricciuti B; Addeo A; Metro G; Ficorella C; Porzio G
Cancer Immunol Immunother; 2020 Nov; 69(11):2209-2221. PubMed ID: 32474768
[TBL] [Abstract][Full Text] [Related]
8. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
9. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
10. Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: A case-control matched analysis from a large multicenter study.
Cortellini A; De Giglio A; Cannita K; Cortinovis DL; Cornelissen R; Baldessari C; Giusti R; D'Argento E; Grossi F; Santoni M; Catino A; Berardi R; Sforza V; Rossi G; Antonuzzo L; Di Noia V; Signorelli D; Gelibter A; Occhipinti MA; Follador A; Rastelli F; Chiari R; Gravara LD; Inno A; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Montrone M; Citarella F; Pensieri MV; Russano M; Cantini L; Nigro O; Leonetti A; Bordi P; Minuti G; Landi L; De Toma A; Donisi C; Ricciardi S; Migliorino MR; Napoli VM; Leone G; Metro G; Banna GL; Friedlaender A; Addeo A; Ficorella C; Porzio G
Thorac Cancer; 2021 Mar; 12(6):880-889. PubMed ID: 33527756
[TBL] [Abstract][Full Text] [Related]
11. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Tamiya M; Tamiya A; Hosoya K; Taniguchi Y; Yokoyama T; Fukuda Y; Hirano K; Matsumoto H; Kominami R; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Kinoshita Y; Hara S; Kumagai T; Fujimoto D
Invest New Drugs; 2019 Dec; 37(6):1266-1273. PubMed ID: 31392549
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
15. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
16. Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
Park JH; You GL; Ahn MJ; Kim SW; Hong MH; Han JY; Ock CY; Lee JS; Oh IJ; Lee SY; Kim CH; Min YJ; Choi YH; Ryu JS; Park SH; Ahn HK; Shim BY; Lee KH; Lee SY; Kim JS; Yi J; Choi SK; An H; Kang JH
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2459-2469. PubMed ID: 33523301
[TBL] [Abstract][Full Text] [Related]
17. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer.
Alessi JV; Ricciuti B; Alden SL; Bertram AA; Lin JJ; Sakhi M; Nishino M; Vaz VR; Lindsay J; Turner MM; Pfaff K; Sharma B; Felt KD; Rodig SJ; Gainor JF; Awad MM
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824161
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
19. KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
Nishio M; Takahashi T; Yoshioka H; Nakagawa K; Fukuhara T; Yamada K; Ichiki M; Tanaka H; Seto T; Sakai H; Kasahara K; Satouchi M; Han SR; Noguchi K; Shimamoto T; Kato T
Cancer Sci; 2019 Mar; 110(3):1012-1020. PubMed ID: 30618179
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
